Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options.
Peritoneal carcinomatosis (PC) can affect quality of life of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Peritoneal disease control by medical therapies in these patients have been poorly investigated Objectives: To describe, in a consecutive series of GEP-NENs, the clinical impact of PC and the effectiveness of available treatments in PC control. Retrospective, monocenter analysis of 135 GEP-NENs (1993-2016) with at least 12-month follow-up. Peritoneal disease progression (DP) was defined as detection of significant increase in size or appearance of new implants by imaging. 62.9% of cases had diffuse PC (involving at least 2 abdominal quadrants). According to WHO 2017 classification patients were 42.3% neuroendocrine tumors NET-G1, 45.5% NET-G2, 6.5% were NET-G3, 4.9% neuroendocrine carcinomas NEC-G3 and 0.8% mixed neuroendocrine-nonneuroendocrine neoplasms. Bowel obstruction occurred in 30 (22.2%) patients mainly depending on nodules' size (HR: 1.10; 95% CI: 1.02-1.20; P = 0.01). Patients with diffuse PC and treated with peptide receptor radionuclide therapy (PRRT) showed peritoneal progression in 37.5% of cases, and bowel obstruction or ascites in 28.1% A better peritoneal disease control was observed in cases receiving somatostatin analogs at first line, probably due to a less aggressive disease behaviour for these patients. Bowel obstruction is not uncommon for GEP-NENs with PC. PRRT should be adopted with caution in GEP-NENs with diffuse PC, but larger series are needed to confirm these data.